← All Cytek Biosciences, INC filings

Cytek Biosciences, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
CTKB
Cytek Biosciences, INC
10-K: Cytek Biosciences Reports Steep Loss Amid Flat Revenue Growth
Cytek Biosciences reported a significant net loss of $66.5 million in 2025, a sharp increase from the previous year, despite minimal 1% revenue growth.
NASDAQ
CTKB
Cytek Biosciences, INC
10-K: Cytek Biosciences Reports FY2024 Results: Revenue Growth Amidst Internal Control Challenges
Cytek Biosciences announces a 4% increase in revenue for fiscal year 2024, reaching $200.5 million, while addressing material weaknesses in internal control over financial reporting.
NASDAQ
CTKB
Cytek Biosciences, INC
10-K: Cytek Biosciences Reports Mixed Results in 2023 Annual Filing, Cites Material Weaknesses in Internal Controls
Cytek Biosciences' 2023 annual report reveals a revenue increase but also a net loss and identifies material weaknesses in internal control over financial reporting.